Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Research output: Contribution to journalComment/debateResearchpeer-review

  1. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Research output: Contribution to journalReviewResearchpeer-review

  • Daniel Heinrich
  • Jasmin Bektic
  • Andries M Bergman
  • Orazio Caffo
  • Richard Cathomas
  • Kim N Chi
  • Gedske Daugaard
  • Daniel Keizman
  • Jon Kindblom
  • Gero Kramer
  • David Olmos
  • Aurelius Omlin
  • Srikala S Sridhar
  • Marcello Tucci
  • Inge van Oort
  • Sten Nilsson
View graph of relations

Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided.

Original languageEnglish
JournalClinical Genitourinary Cancer
Volume16
Issue number1
Pages (from-to)e223-e231
ISSN1938-0682
DOIs
Publication statusPublished - 2018

    Research areas

  • Bone metastases, Patient selection, Targeted alpha therapy, Treatment monitoring, Treatment sequence

ID: 55865862